ReviewJournal of family medicine and primary care2025
Recent advancements in tuberculosis (TB) treatment regimens.
Review in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and validation of a LASSO-derived nomogram for predicting unfavorable treatment outcomes in drug-resistant pulmonary tuberculosis.BMC infectious diseases · 2026Article
- Biodetection of Mycobacterium tuberculosis: nano-biosensors in detection; from principles to recent progresses.Journal of biological engineering · 2026Review
- RpoB mutation patterns in Rifampicin-resistant tuberculosis: a Jiangxi Province study, 2021-2023.Scientific reports · 2025Article
- Congenital tuberculosis in preterm infants in a high-burden setting in southwest China: a single-center cross-sectional study.Frontiers in pediatrics · 2025Article
- Antimycobacterial activity of intertidal sediment-derived bacteria from False Bay, South Africa.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a global health challenge, with an estimated 10.6 million new cases and 1.3 million deaths in 2022. Recent years have seen a 3.9% increase in TB incidence, reversing prior declines. Drug-resistant TB poses significant hurdles, with multidrug-resistant (MDR) and rifampicin-resistant (RR) TB affecting 410,000 individuals, yet only 175,650 were diagnosed and treated. Advances in TB treatment include the World Health Organization's recommended 6-month BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin), demonstrating 89% treatment success for MDR/RR-TB cases. Innovative diagnostics like molecular tests, IGRA, CAD for chest radiography, and new skin tests enhance detection accuracy. Vaccine development is promising, with 16 candidates in clinical trials. Emerging drugs and regimens aim to shorten treatment duration and improve outcomes. This article reviews recent advancements in TB treatment regimens, diagnostics, and vaccines, emphasizing the importance of these innovations in addressing drug-resistant TB and improving global TB control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.